A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

NCT06929299 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Thrombocytopenia (ITP)

Interventions

DRUG: STSA-1301 subcutaneous injection
DRUG: Placebo

Sponsor

Jiangsu BioJeTay Biotechnology Co., Ltd.